Walder Wyss advises Nouscom’s series D investors
Walder Wyss has advised the group of series D investors in the closing of Nouscom’s EUR 120m (USD 135m) financing round. Nouscom is a clinical-stage biotech company focused on cancer interception and developing next-generation immunotherapies.
Deal details
The round was co-led by M Ventures and Revelation Partners. New investors include Angelini Industries, acting through Angelini Investments, and the European Investment Bank, acting through Aurea, its co-investment facility with Angelini Ventures. Neva SGR, part of the Intesa Sanpaolo Group, also joined as a new investor.
Nouscom’s existing investors all took part in the round: 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures.
Advisers
The Walder Wyss team advising the investors was led by Dimitrios Berger (managing associate, corporate/M&A and venture capital) and Karina Tschon (managing associate, corporate/M&A and venture capital). The team also included Alexander Gutmans (partner, corporate/M&A and venture capital), Marion Bähler (partner, corporate/M&A and venture capital) and Merens Derungs (associate, corporate/M&A and venture capital).
